Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS
(Adnkronos) – APDS (activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome) is a rare and progressive primary immunodeficiency Joenja® is a targeted treatment of APDS for adult and pediatric patients 12 years of age
